AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10613615 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral metoprolol tartrate twice daily for a total of nine doses
Number of subjects: 20
Study 10613615 — intervention group
Group type: COMPARATOR
Intervention: Control pharmacodynamic study
Number of subjects: 20
Study 7784593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical balloon declotting
Number of subjects: 40
Study 7784593 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis with urokinase
Number of subjects: 40
Study 1937607 — intervention group
Group type: EXPERIMENTAL
Intervention: High approach (n = 50, group I)
Number of subjects: 100
Study 1937607 — intervention group
Group type: COMPARATOR
Intervention: Low approach (n = 50, group II)
Number of subjects: 100
Study 6942150 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral mandibular manipulation (BMM)
Number of subjects: 30
Study 6942150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin point method (CPM)
Number of subjects: 30
Study 6942150 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior guidance jig (CPJ)
Number of subjects: 30
Study 29146543 — intervention group
Group type: COMPARATOR
Intervention: Interventricular delay optimisation according to QRS complex width measurement (Group 1, n=31)
Number of subjects: 63
Study 29146543 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventricular delay optimisation according to systolic dyssynchrony index (SDI) (Group 2, n=32)
Number of subjects: 63
Study 30027615 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin
Number of subjects: 53
Study 30027615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 27289316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy (IP)
Number of subjects: 135
Study 27289316 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care (CC)
Number of subjects: 135
Study 24885201 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (10,000 IU/week)
Number of subjects: 600
Study 24885201 — intervention group
Group type: EXPERIMENTAL
Intervention: Gargling
Number of subjects: 600
Study 24885201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 24885201 — intervention group
Group type: COMPARATOR
Intervention: No Gargling
Number of subjects: 600
Study 22466329 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 170
Study 22466329 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Adefovir dipivoxil (ADV)
Number of subjects: 170
Study 20097600 — intervention group
Group type: EXPERIMENTAL
Intervention: Email (n=40)
Number of subjects: 196
Study 20097600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fax (n=48)
Number of subjects: 196
Study 20097600 — intervention group
Group type: COMPARATOR
Intervention: Post (n=40)
Number of subjects: 196
Study 20097600 — intervention group
Group type: COMPARATOR
Intervention: Patient hand delivery (n=40)
Number of subjects: 196
Study 18084985 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushed epidural catheters
Number of subjects: 20
Study 18084985 — intervention group
Group type: COMPARATOR
Intervention: Unflushed epidural catheters
Number of subjects: 20
Study 16112720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg, IV)
Number of subjects: 25
Study 16112720 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (30 mg, IV)
Number of subjects: 25
Study 12161475 — intervention group
Group type: COMPARATOR
Intervention: T patch alone (Testoderm TTS, 5 mg/d)
Number of subjects: 39
Study 12161475 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant II (Jadelle, 160 microg/d LNG) plus T patch
Number of subjects: 39
Study 12161475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral LNG (125 microg/d) plus T patch
Number of subjects: 39
Study 12161475 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant II plus T enanthate (TE) injection (100 mg/wk i.m.)
Number of subjects: 39
Study 9895373 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric tonometry during exercise
Number of subjects: 14
Study 9895373 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric tonometry after revascularisation
Number of subjects: 14
Study 7575695 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cM‐T412
Number of subjects: 7
Study 7575695 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg cM‐T412
Number of subjects: 7
Study 7575695 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg cM‐T412
Number of subjects: 7
Study 7575695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31971325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfetalness
Number of subjects: 39865
Study 30360898 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention on inhaler technique
Number of subjects: 97
Study 30360898 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 97
Study 28737861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in asthma patients
Number of subjects: 72
Study 28737861 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control and severity in patients with vitamin D deficiency
Number of subjects: 72
Study 28737861 — intervention group
Group type: COMPARATOR
Intervention: Comparison of vitamin D levels with control group
Number of subjects: 72
Study 28737861 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of vitamin D levels with other factors
Number of subjects: 72
Study 26282659 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cups/d or more of total coffee
Number of subjects: 953
Study 26282659 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cups/d or more of caffeinated coffee
Number of subjects: 953
Study 26282659 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing caffeine intake
Number of subjects: 953
Study 26282659 — intervention group
Group type: COMPARATOR
Intervention: Nonherbal tea and decaffeinated coffee
Number of subjects: 953
Study 24701774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stabilization system (ligamentoplasty) placed in the segment above (group L)
Number of subjects: 58
Study 24701774 — intervention group
Group type: COMPARATOR
Intervention: No dynamic stabilization system (group S)
Number of subjects: 58
Study 22090496 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary action preparation
Number of subjects: 0
Study 22090496 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus-driven response
Number of subjects: 0
Study 19054552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon 10 mg
Number of subjects: 450
Study 19054552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon 20 mg
Number of subjects: 450
Study 19054552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon 50 mg
Number of subjects: 450
Study 19054552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon 100 mg
Number of subjects: 450
Study 19054552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 17302061 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM treatment beginning with Fei (SLE I formula in active stage or SLE II formula in silent period)
Number of subjects: 110
Study 17302061 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicinal treatment
Number of subjects: 110
Study 15487320 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole therapy
Number of subjects: 205
Study 15487320 — intervention group
Group type: COMPARATOR
Intervention: No antifungal therapy
Number of subjects: 205
Study 11564360 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group receiving videoconferencing and Internet access in addition to standard care
Number of subjects: 28
Study 11564360 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 28
Study 9782602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (3 x 400 mg RRR‐alpha‐Tocopherolacetat/d)
Number of subjects: 85
Study 9782602 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium
Number of subjects: 85
Study 7823520 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shields with vitamin A and Epidermal Growth Factor (EGF)
Number of subjects: 28
Study 7823520 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shields without additives
Number of subjects: 28
Study 7823520 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shields with retinyl palmitate
Number of subjects: 28
Study 7823520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no collagen shields)
Number of subjects: 28
Study 3350204 — intervention group
Group type: EXPERIMENTAL
Intervention: Brufen
Number of subjects: 17
Study 3350204 — intervention group
Group type: EXPERIMENTAL
Intervention: Burana
Number of subjects: 17
Study 3350204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibumetin
Number of subjects: 17
Study 29491500 — intervention group
Group type: EXPERIMENTAL
Intervention: MyDispense
Number of subjects: 0
Study 29491500 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper methods
Number of subjects: 0
Study 29491500 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional outside-of-class cases using MyDispense
Number of subjects: 0
Study 28327893 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone)
Number of subjects: 285
Study 28327893 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC and BCL2 coexpression
Number of subjects: 285
Study 26083656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate (325 mg three times daily for 8 weeks)
Number of subjects: 136
Study 26083656 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron sucrose (200 mg every 2 weeks, total 1 g)
Number of subjects: 136
Study 26083656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate
Number of subjects: 136
Study 26083656 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron sucrose
Number of subjects: 136
Study 23016924 — intervention group
Group type: COMPARATOR
Intervention: ABT-288 single doses (0.1, 0.3, 1, 3, 10, 20, and 40 mg)
Number of subjects: 0
Study 23016924 — intervention group
Group type: COMPARATOR
Intervention: ABT-288 multiple doses (0.5, 1.5, 3, and 6 mg once-daily for 14 days in young adults)
Number of subjects: 0
Study 23016924 — intervention group
Group type: COMPARATOR
Intervention: ABT-288 multiple doses (0.5, 1.5, 3, and 5 mg once-daily for 12 days in elderly subjects)
Number of subjects: 0
Study 23016924 — intervention group
Group type: COMPARATOR
Intervention: ABT-288 (5 mg single dose) with food
Number of subjects: 0
Study 21118746 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of oral risperidone 2 mg
Number of subjects: 22
Study 21118746 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of oral risperidone 2 mg
Number of subjects: 22
Study 18200463 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose diathermy technique
Number of subjects: 40
Study 18200463 — intervention group
Group type: COMPARATOR
Intervention: Scissors technique
Number of subjects: 40
Study 16903819 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP (Photovaporization of the prostate)
Number of subjects: 120
Study 16903819 — intervention group
Group type: COMPARATOR
Intervention: TURP (Transurethral resection of the prostate)
Number of subjects: 120
Study 12811310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 7 days
Number of subjects: 48
Study 12811310 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 7 days
Number of subjects: 48
Study 10760645 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 398
Study 10760645 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 398
Study 8923017 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of vegetables and fruit
Number of subjects: 0
Study 8923017 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (vitamin C, vitamin E, beta-carotene, selenium, magnesium, zinc)
Number of subjects: 0
Study 8923017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre
Number of subjects: 0
Study 8923017 — intervention group
Group type: COMPARATOR
Intervention: Various combinations of vitamins and minerals at supranutritional doses
Number of subjects: 0
Study 1739545 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheal intubation with thiopentone
Number of subjects: 24
Study 1739545 — intervention group
Group type: COMPARATOR
Intervention: Control method (3 min of manual ventilation)
Number of subjects: 24
Study 6391784 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg (for cisplatin >= 100 mg/sq m) or 1.25 mg (for subsequent doses < 100 mg/sq m)
Number of subjects: 25
Study 6391784 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 2 mg/kg (for cisplatin >= 100 mg/sq m) or 1 mg/kg (for subsequent doses < 100 mg/sq m)
Number of subjects: 25
Study 6391784 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg (for both dosages of cisplatin)
Number of subjects: 25
Study 31259802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tightrope fixation (one knotless Tightrope)
Number of subjects: 103
Study 31259802 — intervention group
Group type: COMPARATOR
Intervention: Screw fixation (two 3.5 mm cortical positional screws)
Number of subjects: 103
Study 31259802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tightrope fixation
Number of subjects: 103
Study 31259802 — intervention group
Group type: COMPARATOR
Intervention: Screw fixation
Number of subjects: 103
Study 31259802 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcomes (FADI scores)
Number of subjects: 103
Study 28754540 — intervention group
Group type: EXPERIMENTAL
Intervention: P3P (Personal Patient Profile‐Prostate) decision aid
Number of subjects: 392
Study 28754540 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392
Study 27008285 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation therapy
Number of subjects: 59
Study 27008285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stress
Number of subjects: 59
Study 27008285 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 59
Study 24170102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracosactide (ACTH1‐24) therapy
Number of subjects: 13
Study 22186968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital loading dose of 600 mg clopidogrel
Number of subjects: 337
Study 22186968 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (clopidogrel administered after diagnostic angiogram)
Number of subjects: 337
Study 22186968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital loading dose of 600 mg clopidogrel (treated patients)
Number of subjects: 337
Study 22186968 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (treated patients)
Number of subjects: 337
Study 22186968 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 337
Study 20107434 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 0.5 mg b.i.d.
Number of subjects: 2000
Study 20107434 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d.
Number of subjects: 2000
Study 20107434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 20107434 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. (Male)
Number of subjects: 2000
Study 20107434 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. (Female)
Number of subjects: 2000
Study 17327628 — intervention group
Group type: EXPERIMENTAL
Intervention: Graves' Disease group
Number of subjects: 19
Study 17327628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 14551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation oral contraceptive (30 microg ethinylestradiol/150 microg levonorgestrel)
Number of subjects: 86
Study 14551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation oral contraceptive (30 microg ethinylestradiol/150 microg desogestrel)
Number of subjects: 86
Study 14551147 — intervention group
Group type: COMPARATOR
Intervention: Progestagen-only preparations
Number of subjects: 86
Study 11216928 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line protease inhibitor regimen (specific PIs include indinavir and nelfinavir)
Number of subjects: 984
Study 11216928 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line protease inhibitor regimen with added nucleosides
Number of subjects: 984
Study 11216928 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher viral load at starting second PI
Number of subjects: 984
Study 11216928 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CD4 cell count at starting second PI
Number of subjects: 984
Study 9522133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 40
Study 9522133 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral 3-in-1 block with 0.5% bupivacaine 2 mg kg-1
Number of subjects: 40
Study 8026196 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐beta‐hydroxybutyrate infusion
Number of subjects: 12
Study 8026196 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 12
Study 2644580 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-86 (cholinergic agonist)
Number of subjects: 10
Study 2644580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 193743 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoseptil Ear Drops
Number of subjects: 58
Study 193743 — intervention group
Group type: COMPARATOR
Intervention: Otosporin Ear Drops
Number of subjects: 58
Study 31521496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage Treatment (LT) group
Number of subjects: 60
Study 31521496 — intervention group
Group type: COMPARATOR
Intervention: Dependent Drainage (DD) group
Number of subjects: 60
Study 28235691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation condition (29 consecutive hours awake)
Number of subjects: 40
Study 28235691 — intervention group
Group type: COMPARATOR
Intervention: Control condition (normal sleep)
Number of subjects: 40
Study 25548861 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week sensory cueing treatment
Number of subjects: 12
Study 25548861 — intervention group
Group type: COMPARATOR
Intervention: 3-week sham treatment
Number of subjects: 12
Study 24703167 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Iyengar yoga intervention
Number of subjects: 31
Study 24703167 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 31
Study 22824168 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine (4 g) for 12 weeks
Number of subjects: 72
Study 22824168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19670114 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Ultrasonic scalpel
Number of subjects: 51
Study 19670114 — intervention group
Group type: COMPARATOR
Intervention: Scissors and hemostatic clips
Number of subjects: 51
Study 18154124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 6 mg/m2 intravenously, daily; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Number of subjects: 0
Study 18154124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2, weekly; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Number of subjects: 0
Study 18154124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2, once in 3 weeks; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Number of subjects: 0
Study 15131005 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitor (ramipril)
Number of subjects: 64
Study 15131005 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1 antagonist (valsartan)
Number of subjects: 64
Study 15131005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15131005 — intervention group
Group type: COMPARATOR
Intervention: Control group (valve replacement for mitral stenosis)
Number of subjects: 64
Study 11588449 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic bypass (36 degrees C, n = 8)
Number of subjects: 21
Study 11588449 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB (32 degrees C, n = 13)
Number of subjects: 21
Study 11588449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 9442789 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate overcorrection (50%) in patients with minimal haze after first PRK
Number of subjects: 106
Study 9442789 — intervention group
Group type: EXPERIMENTAL
Intervention: Exact retreatment in patients with minimal haze after first PRK
Number of subjects: 106
Study 9442789 — intervention group
Group type: EXPERIMENTAL
Intervention: Exact retreatment in patients with significant haze (> or = 2+ haze)
Number of subjects: 106
Study 9442789 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate overcorrection (50%) in patients with significant haze (> or = 2+ haze)
Number of subjects: 106
Study 9442789 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study 8801333 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-A (microporous membrane/acrylic adhesive)
Number of subjects: 10
Study 8801333 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-B (microporous membrane/silicone adhesive)
Number of subjects: 10
Study 8801333 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-C (microporous membrane)
Number of subjects: 10
Study 2083043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% copolymer in a 0.243% sodium fluoride silica base
Number of subjects: 147
Study 2083043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% copolymer in a 0.76% sodium monofluorophosphate alumina base
Number of subjects: 147
Study 2083043 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 147
Study 464673 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose with an amino acid solution containing 22% BCAAs
Number of subjects: 35